AI assistant
USCOM LIMITED — Regulatory Filings 2009
Sep 2, 2009
65979_rns_2009-09-02_5e73b260-91b1-4719-a6f4-788c02f7679e.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [71 x 87] intentionally omitted <==
MARKET ANNOUNCEMENT
USCOM standard of care presentation at World Federation meeting
Thursday, 3 September 2009: Uscom (ASX Code: UCM) today notified shareholders of a new presentation at the World Federation of Ultrasound In Medicine and Biology, 12[th] World Congress in Sydney citing USCOM as a standard of care in Fluid Management, Pediatric sepsis, ICU, Organ Procurement and Liver Transplantation.
The presentation titled “USCOM; A New Standard for Circulatory Management in Critical Care” by Uscom Executive Chairman and Director of Clinical Science, Rob Phillips summarised the evidence in current scientific literature supporting standard of care status for the USCOM 1A. These standard of care statements have been published over the last year. Mr Phillips was an invited speaker at the Congress and presented three academic papers.
Uscom CEO, Mr. Paul Butler said “This is a great opportunity to present our science to the people of the global ultrasound community and update them on the rapidly expanding evidence supporting USCOM use in a variety of clinical applications.”
Mr Rob Phillips, Executive Chairman and Director of Clinical Science said “This presentation highlights the increasing global recognition of the usefulness of the USCOM technology and summarises the recently published evidence and opinions of independent world experts.”
www.uscom.com.au
Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090
==> picture [71 x 87] intentionally omitted <==
About Uscom
Uscom Limited is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a device for the safe and accurate measurement of cardiac output, a non-invasive alternative to the current invasive methods. Uscom offers a completely safe, painless and quick method of accurately measuring how well the heart is pumping. With its real-time beat-to-beat information across multiple parameters of cardiac function and advanced serial measurement capabilities, clinicians can accurately quantify the impact of therapy. The device is ideally suited to the Emergency Care setting where it is critical to monitor changes in cardiac output as fluids are applied.
The Company has secured regulatory approval for sale of the Uscom Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).
Uscom Contacts Paul Butler Chief Executive Officer Office: 02 9247 4144 [email protected]
Rob Phillips Executive Chairman Office: 02 9247 4144 [email protected]
www.uscom.com.au
Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090